Value For Money In The Treatment Of Patients With Type 2 Diabetes Mellitus: Assessing The Long-Term Cost-Effectiveness Of IDegLira Versus iGlarLixi In Italy

Figures & data

Table 1 Treatment Effects Applied In The Analysis

	IDegLira	iGlarLixi
Change in HbA1c (%) [mmol/mol]	–1.9 [−21]	–1.5 [−16]
Change in BMI (kg/m^2)	–0.92	–0.41
Daily dose (units)	45.00	48.60
NSHE rate (events per 100 patient-years)	152.3	298.63
SHE rate (events per 100 patient-years)	1.10	2.16

Abbreviations: BMI, body mass index; HbA1c, glycated hemoglobin; NSHE, non-severe hypoglycemic event; SHE, severe hypoglycemic event.

Figure 1 Cumulative Incidence Of Diabetes-Related Complications.

Abbreviations: BDR, background diabetic retinopathy; CHF, congestive heart failure; ESRD, end-stage renal disease; GRP, gross proteinuria; MA, microalbuminuria ME, macular edema; MI, myocardial infarction; PDR, proliferative diabetic retinopathy; PVD, peripheral vascular disease; Rec., recurring; SVL, severe vision loss.

Table 2 Long-Term Cost-Effectiveness Outcomes

	IDegLira	iGlarLixi	Difference
Discounted life expectancy (years)	14.58	14.49	+0.09
Discounted quality-adjusted life expectancy (QALYs)	9.35	9.23	+0.13
Discounted direct costs (EUR)	62,886	61,956	+930
ICER (based on quality-adjusted life expectancy)	EUR 7,368 per QALY gained

Note: Rounding may lead to variation in the values shown in the Difference column.

Abbreviations: EUR, 2017 Euros; ICER, incremental cost-effectiveness ratio; QALYs, quality-adjusted life years.

Figure 2 Results of deterministic sensitivity analyses.

Abbreviations: BMI, body mass index; CI, confidence interval; EUR, 2017 Euros; HbA1c, glycated hemoglobin; ICER, incremental cost-effectiveness ratio; QALY, quality-adjusted life year; SMBG, self-monitoring of blood glucose; UKPDS, United Kingdom Prospective Diabetes Study; WTP, willingness-to-pay.

Figure 3 Cost-effectiveness acceptability curve.

Abbreviations: EUR, 2017 Euros; QALY, quality-adjusted life year; WTP, willingness to pay.